Global Retinal Biologics 麻豆原创 Research Report 2023

Publication ID:

PB510240576

Publication Date:

October 11, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Many retinal biologics have been approved by the Food and Drug Administration (FDA), the European Medicine Agency (EMA) and the China Food and Drug Administration (CFDA) for the treatment of retinal diseases. Advancements in technologies and new mechanism of action for different biologics to treat retinal diseases are anticipated to boost the retinal biologics market.
The global Retinal Biologics market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Retinal Biologics market research.
Key companies engaged in the Retinal Biologics industry include Spark Therapeutics, Inc, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc, AbbVie Inc, Johnson & Johnson Services, Inc and Amgen Inc, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Retinal Biologics were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Retinal Biologics market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Retinal Biologics market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Spark Therapeutics, Inc
F. Hoffmann-La Roche Ltd
Regeneron Pharmaceuticals, Inc
AbbVie Inc
Johnson & Johnson Services, Inc
Amgen Inc
Segment by Type
Macular Degeneration
Diabetic Retinopathy
Diabetic Macular Edema
Uveitis
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Retinal Biologics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Retinal Biologics 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Macular Degeneration
1.2.3 Diabetic Retinopathy
1.2.4 Diabetic Macular Edema
1.2.5 Uveitis
1.2.6 Others
1.3 麻豆原创 by Application
1.3.1 Global Retinal Biologics 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Retinal Biologics 麻豆原创 Perspective (2018-2029)
2.2 Retinal Biologics Growth Trends by Region
2.2.1 Global Retinal Biologics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Retinal Biologics Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Retinal Biologics Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Retinal Biologics 麻豆原创 Dynamics
2.3.1 Retinal Biologics Industry Trends
2.3.2 Retinal Biologics 麻豆原创 Drivers
2.3.3 Retinal Biologics 麻豆原创 Challenges
2.3.4 Retinal Biologics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Retinal Biologics Players by Revenue
3.1.1 Global Top Retinal Biologics Players by Revenue (2018-2023)
3.1.2 Global Retinal Biologics Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Retinal Biologics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Retinal Biologics Revenue
3.4 Global Retinal Biologics 麻豆原创 Concentration Ratio
3.4.1 Global Retinal Biologics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Retinal Biologics Revenue in 2022
3.5 Retinal Biologics Key Players Head office and Area Served
3.6 Key Players Retinal Biologics Product Solution and Service
3.7 Date of Enter into Retinal Biologics 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Retinal Biologics Breakdown Data by Type
4.1 Global Retinal Biologics Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Retinal Biologics Forecasted 麻豆原创 Size by Type (2024-2029)
5 Retinal Biologics Breakdown Data by Application
5.1 Global Retinal Biologics Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Retinal Biologics Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Retinal Biologics 麻豆原创 Size (2018-2029)
6.2 North America Retinal Biologics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Retinal Biologics 麻豆原创 Size by Country (2018-2023)
6.4 North America Retinal Biologics 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Retinal Biologics 麻豆原创 Size (2018-2029)
7.2 Europe Retinal Biologics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Retinal Biologics 麻豆原创 Size by Country (2018-2023)
7.4 Europe Retinal Biologics 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Retinal Biologics 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Retinal Biologics 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Retinal Biologics 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Retinal Biologics 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Retinal Biologics 麻豆原创 Size (2018-2029)
9.2 Latin America Retinal Biologics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Retinal Biologics 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Retinal Biologics 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Retinal Biologics 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Retinal Biologics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Retinal Biologics 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Retinal Biologics 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Spark Therapeutics, Inc
11.1.1 Spark Therapeutics, Inc Company Detail
11.1.2 Spark Therapeutics, Inc Business Overview
11.1.3 Spark Therapeutics, Inc Retinal Biologics Introduction
11.1.4 Spark Therapeutics, Inc Revenue in Retinal Biologics Business (2018-2023)
11.1.5 Spark Therapeutics, Inc Recent Development
11.2 F. Hoffmann-La Roche Ltd
11.2.1 F. Hoffmann-La Roche Ltd Company Detail
11.2.2 F. Hoffmann-La Roche Ltd Business Overview
11.2.3 F. Hoffmann-La Roche Ltd Retinal Biologics Introduction
11.2.4 F. Hoffmann-La Roche Ltd Revenue in Retinal Biologics Business (2018-2023)
11.2.5 F. Hoffmann-La Roche Ltd Recent Development
11.3 Regeneron Pharmaceuticals, Inc
11.3.1 Regeneron Pharmaceuticals, Inc Company Detail
11.3.2 Regeneron Pharmaceuticals, Inc Business Overview
11.3.3 Regeneron Pharmaceuticals, Inc Retinal Biologics Introduction
11.3.4 Regeneron Pharmaceuticals, Inc Revenue in Retinal Biologics Business (2018-2023)
11.3.5 Regeneron Pharmaceuticals, Inc Recent Development
11.4 AbbVie Inc
11.4.1 AbbVie Inc Company Detail
11.4.2 AbbVie Inc Business Overview
11.4.3 AbbVie Inc Retinal Biologics Introduction
11.4.4 AbbVie Inc Revenue in Retinal Biologics Business (2018-2023)
11.4.5 AbbVie Inc Recent Development
11.5 Johnson & Johnson Services, Inc
11.5.1 Johnson & Johnson Services, Inc Company Detail
11.5.2 Johnson & Johnson Services, Inc Business Overview
11.5.3 Johnson & Johnson Services, Inc Retinal Biologics Introduction
11.5.4 Johnson & Johnson Services, Inc Revenue in Retinal Biologics Business (2018-2023)
11.5.5 Johnson & Johnson Services, Inc Recent Development
11.6 Amgen Inc
11.6.1 Amgen Inc Company Detail
11.6.2 Amgen Inc Business Overview
11.6.3 Amgen Inc Retinal Biologics Introduction
11.6.4 Amgen Inc Revenue in Retinal Biologics Business (2018-2023)
11.6.5 Amgen Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Spark Therapeutics, Inc
F. Hoffmann-La Roche Ltd
Regeneron Pharmaceuticals, Inc
AbbVie Inc
Johnson & Johnson Services, Inc
Amgen Inc

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.